Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

Nature Biotechnology

Volumn 25, Issue 9, 2007, Pages 1035-1044

  Bantscheff, Marcus ^a   Eberhard, Dirk ^a   Abraham, Yann ^a   Bastuck, Sonja ^a   Boesche, Markus ^a   Hobson, Scott ^a   Mathieson, Toby ^a   Perrin, Jessica ^a   Raida, Manfred ^a   Rau, Christina ^a   Reader, Valérie ^b   Sweetman, Gavain ^a   Bauer, Andreas ^a   Bouwmeester, Tewis ^a   Hopf, Carsten ^a   Kruse, Ulrich ^a   Neubauer, Gitte ^a   Ramsden, Nigel ^b   Rick, Jens ^a   Kuster, Bernhard ^a   Drewes, Gerard ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b Cellzome Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CELLS; DRUG PRODUCTS; ENZYME INHIBITION; MOLECULAR STRUCTURE;

BINDING PROTEINS; DRUG DISCOVERY; KINASE INHIBITORS;

PROTEINS;

BOSUTINIB; DASATINIB; IMATINIB; OXIDOREDUCTASE; PHOSPHOTRANSFERASE INHIBITOR; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL LYSATE; DRUG BINDING; DRUG MECHANISM; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

CELL EXTRACTS; CHROMATOGRAPHY, AFFINITY; ENZYMES, IMMOBILIZED; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; PHARMACEUTICAL PREPARATIONS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; QUINONE REDUCTASES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 34948875686     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1328     Document Type: Article

References (50)

1. Hall, S.E. Chemoproteomics-driven drug discovery: addressing high attrition rates. Drug Discov. Today 11, 495-502 (2006).
2. Morphy, R., Kay, C. & Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today 9, 641-651 (2004).
3. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315 (2002).
4. Liu, Y. & Gray, N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364 (2006).
5. Daub, H., Specht, K. & Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3, 1001-1010 (2004).
6. Mol, C.D., Fabbro, D. & Hosfield, D.J. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr. Opin. Drug Discov. Devel. 7, 639-648 (2004).
7. Fabbro, D. & Garcia-Echeverria, C. Targeting protein kinases in cancer therapy. Curr. Opin. Drug Discov. Devel. 5, 701-712 (2002).
8. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
9. Haystead, T.A. The purinome, a complex mix of drug and toxicity targets. Curr. Top. Med. Chem. 6, 1117-1127 (2006).
10. Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
11. Fliri, A.F., Loging, W.T., Thadeio, P.F. & Volkmann, R.A. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat. Chem. Biol. 1, 389-397 (2005).
12. Szardenings, K., Li, B., Ma, L. & Wu, M. Fishing for targets: novel approaches using small molecule baits. Drug Discov. Today: Technologies 3, 9-15 (2004).
13. Godl, K. et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. USA 100, 15434-15439 (2003).
14. Knockaert, M. et al. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem. Biol. 7, 411-422 (2000).
15. Ross, P.L. et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3, 1154-1169 (2004).
16. Hantschel, O. & Superti-Furga, G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 33-44 (2004).
17. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493-502 (2002).
18. Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A. & Griffin, J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7, 345-356 (2007).
19. Ding, S. et al. Synthetic small molecules that control stem cell fate. Proc. Natl. Acad. Sci. USA 100, 7632-7637 (2003).
20. Rappsilber, J., Ryder, U., Lamond, A.I. & Mann, M. Large-scale proteomic analysis of the human spliceosome. Genome Res. 12, 1231-1245 (2002).
21. Wissing, J. et al. Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol. Cell. Proteomics 3, 1181-1193 (2004).
22. Graves, P.R. et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364-1372 (2002).
23. Golas, J.M. et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63, 375-381 (2003).
24. Kantarjian, H., Jabbour, E., Grimley, J. & Kirkpatrick, P. Dasatinib. Nat. Rev. Drug Discov. 5, 717-718 (2006).
25. Druker, B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
26. Carter, T.A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102, 11011-11016 (2005).
27. Kowanetz, K. et al. Suppressors of T-cell receptor signaling Sts-1 and Sts-2 bind to Cbl and inhibit endocytosis of receptor tyrosine kinases. J. Biol. Chem. 279, 32786-32795 (2004).
28. Tuveson, D.A. et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054-5058 (2001).
29. Su, A.I. et al. Large-scale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. USA 99, 4465-4470 (2002).
30. L'hote, C.G., Thomas, P.H. & Ganesan, T.S. Functional analysis of discoidin domain receptor 1: effect of adhesion on DDR1 phosphorylation. FASEB J. 16, 234-236 (2002).
31. Vella, F., Ferry, G., Delagrange, P. & Boutin, J.A. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol. 71, 1-12 (2005).
32. Knox, R.J. et al. Bioactivation of 5-(aziridin-1-yl)-2,4- dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res. 60, 4179-4186 (2000).
33. Patricelli, M.P. et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46, 350-358 (2007).
34. Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621-637 (2005).
35. Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104 (1996).
36. Lombardo, L.J. et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2- (6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661 (2004).
37. Lowe, C.R., Harvey, M.J., Craven, D.B. & Dean, P.D. Some parameters relevant to affinity chromatography on immobilized nucleotides. Biochem. J. 133, 499-506 (1973).
38. Vogel, W.F., Abdulhussein, R. & Ford, C.E. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell. Signal. 18, 1108-1116 (2006).
39. Ongusaha, P.P. et al. p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J. 22, 1289-1301 (2003).
40. Rossler, J., Zambrzycka, I., Lagodny, J., Kontny, U. & Niemeyer, C.M. Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells. Biochem. Biophys. Res. Commun. 342, 1405-1412 (2006).
41. Avivi-Green, C., Singal, M. & Vogel, W.F. Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. Am. J. Respir. Crit. Care Med. 174, 420-427 (2006).
42. Daniels, C.E. et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 114, 1308-1316 (2004).
43. Kneidinger, M. et al. Dasatinib (BMS354825) inhibits IgE-dependent activation and histamine release in human blood basophils. Blood 108 Abs. 1365 (2006).
44. Shah, N.P. et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108, 286-291 (2006).
45. Yang, T.T., Xiong, Q., Graef, I.A., Crabtree, G.R. & Chow, C.W. Recruitment of the extracellular signal-regulated kinase/ribosomal S6 kinase signaling pathway to the NFATc4 transcription activation complex. Mol. Cell. Biol. 25, 907-920 (2005).
46. Drewes, G. et al. Process for the identification of novel enzyme interacting compounds. Patent WO 2006/134056 A1 (2006).
47. Boschelli, D.H. et al. 7-Alkoxy-4-phenylamino-3-quinolinecar- bonitriles as dual inhibitors of Src and Abl kinases. J. Med. Chem. 47, 1599-1601 (2004).
48. Das, J. et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)] -2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 49, 6819-6832 (2006).
49. Shevchenko, A., Wilm, M., Vorm, O. & Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850-858 (1996).
50. Pozuelo, R.M., Campbell, D.G., Morrice, N.A. & Mackintosh, C. Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem. J. 392, 163-172 (2005).